Three biotechs, two Chinese issuers, and one SPAC went public this past week, led by preclinical oncology biotech Nkarta (NKTX), which popped 166% in the best first-day return for a $10+ million IPO since 2015.
Some major news hit the IPO...read more
Poseida Therapeutics, a Phase 2 biotech developing CAR T cell therapies for multiple myeloma, raised $224 million by offering 14 million shares at the $16, in line with the upwardly revised terms. The company originally planned to offer 10 million shares at $14...read more
Poseida Therapeutics, a phase 2 biotech developing CAR T cell therapies for multiple myeloma, raised the proposed deal size for its upcoming IPO on Thursday. The San Diego, CA-based company now plans to raise $224 million by offering 14 million shares at a...read more
Poseida Therapeutics, a Phase 2 biotech developing CAR T cell therapies for multiple myeloma, announced terms for its IPO on Monday.
The San Diego, CA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At...read more
US IPO Weekly Recap: Preclinical biotech Nkarta pops 166% in a 5 IPO week
Three biotechs, two Chinese issuers, and one SPAC went public this past week, led by preclinical oncology biotech Nkarta (NKTX), which popped 166% in the best first-day return for a $10+ million IPO since 2015. Some major news hit the IPO...read more
Oncology biotech Poseida Therapeutics prices upsized IPO at $16, in line with upwardly revised terms
Poseida Therapeutics, a Phase 2 biotech developing CAR T cell therapies for multiple myeloma, raised $224 million by offering 14 million shares at the $16, in line with the upwardly revised terms. The company originally planned to offer 10 million shares at $14...read more
Oncology biotech Poseida Therapeutics raises proposed deal size by 49% ahead of $224 million IPO
Poseida Therapeutics, a phase 2 biotech developing CAR T cell therapies for multiple myeloma, raised the proposed deal size for its upcoming IPO on Thursday. The San Diego, CA-based company now plans to raise $224 million by offering 14 million shares at a...read more
Oncology biotech Poseida Therapeutics sets terms for $150 million IPO
Poseida Therapeutics, a Phase 2 biotech developing CAR T cell therapies for multiple myeloma, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At...read more